Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 63, Issue 11, 2011, Pages 3502-3511

  Mathian, A ^a,c   Devilliers, H ^a,d   Krivine, A ^b   Costedoat Chalumeau, N ^a   Haroche, J ^a   Huong, D Boutin Le Thi ^a   Wechsler, B ^a   Hervier, B ^a,c   Miyara, M ^a,c   Morel, N ^a   Le Corre, N ^a   Arnaud, L ^a,c   Piette, J C ^a   Musset, L ^a   Autran, B ^a   Rozenberg, F ^b   Amoura, Z ^a,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b université Paris Cité   (France)

^c INSERM   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; INFLUENZA VACCINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ANTIBODY RESPONSE; ARTICLE; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PANDEMIC INFLUENZA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEROCONVERSION; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINE FAILURE;

ADULT; ANTIBODY FORMATION; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80155130107     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30576     Document Type: Article

References (49)

1. Centers for Disease Control and Prevention. Swine influenza A (H1N1) infection in two childrenâSouthern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 400-2.
2. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325: 197-201.
3. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361: 1945-52.
4. Staples PJ, Gerding DN, Decker JL, Gordon RS Jr,. Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 1974; 17: 1-10.
5. Kallenberg CG, Limburg PC, Van Slochteren C, Van Der Woude FJ, The TH,. B cell activity in systemic lupus erythematosus: depressed in vivo humoral immune response to a primary antigen (haemocyanin) and increased in vitro spontaneous immunoglobulin synthesis. Clin Exp Immunol 1983; 53: 371-83. (Pubitemid 13076719)
6. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-7. (Pubitemid 44205016)
7. Kunisaki KM, Janoff EN,. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9: 493-504.
8. Ristow SC, Douglas RG Jr, Condemi JJ,. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 1978; 88: 786-9. (Pubitemid 8351380)
9. Williams GW, Steinberg AD, Reinertsen JL, Klassen LW, Decker JL, Dolin R,. Influenza immunization in systemic lupus eruthematosus: a double-blind trial. Ann Intern Med 1978; 88: 729-34. (Pubitemid 8351370)
10. Brodman R, Gilfillan R, Glass D, Schur PH,. Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med 1978; 88: 735-40. (Pubitemid 8351371)
11. Louie JS, Nies KM, Shoji KT, Fraback RC, Abrass C, Border W, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 1978; 88: 790-2.
12. Herron A, Dettleff G, Hixon B, Brandwin L, Ortbals D, Hornick R, et al. Influenza vaccination in patients with rheumatic diseases: safety and efficacy. JAMA 1979; 242: 53-6.
13. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V,. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol 2001; 19: 589-94. (Pubitemid 32894612)
14. Del Porto F, Lagana B, Biselli R, Donatelli I, Campitelli L, Nisini R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis: safety and immunogenicity. Vaccine 2006; 24: 3217-23.
15. Mercado U, Acosta H, Avendano L,. Influenza vaccination of patients with systemic lupus erythematosus. Rev Invest Clin 2004; 56: 16-20. (Pubitemid 38559467)
16. Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006; 65: 913-8.
17. Wallin L, Quintilio W, Locatelli F, Cassel A, Silva MB, Skare TL,. Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients. Acta Reumatol Port 2009; 34: 498-502.
18. Wiesik-Szewczyk E, Romanowska M, Mielnik P, Chwalinska-Sadowska H, Brydak LB, Olesinska M, et al. Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clin Rheumatol 2010; 29: 605-13.
19. Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D,. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol 2000; 27: 1681-5. (Pubitemid 30462811)
20. Abu-Shakra M, Press J, Sukenik S, Buskila D,. Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies. Clin Rheumatol 2002; 21: 369-72.
21. Haut Conseil de la santé publique. Actualisation de l'avis relatif aux recommandations sur l'utilisation des vaccins pandémiques dirigés contre le virus grippal A(H1N1)v: 28 octobre 2009. URL:.
22. Salemi S, D'Amelio R,. Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol 2010; 29: 270-314.
23. Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010; 49: 1815-27.
24. Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002; 29: 2555-7. (Pubitemid 35416961)
25. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
26. Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology (Oxford) 2009; 48: 1294-9.
27. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361: 2405-13.
28. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
29. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142: 953-62.
30. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550-8. (Pubitemid 41785892)
31. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 902-6. (Pubitemid 41511186)
32. Yee CS, Farewell V, Isenberg DA, Griffiths B, Teh LS, Bruce IN, et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) 2009; 48: 691-5.
33. Karlson EW, Daltroy LH, Rivest C, Ramsey-Goldman R, Wright EA, Partridge AJ, et al. Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus 2003; 12: 280-6. (Pubitemid 36458658)
34. Kendal AP, Pereira MS, Skehel JJ, editors. Concepts and procedures for laboratory-based influenza surveillance. Atlanta (GA): Department of Health and Human Services (US), CDC; 1982.
35. European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. London: European Medicines Agency, 1996. Publication No: CPMP/BWP/214/96. URL:.
36. Department of Health and Human Services (US), Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. May 2007. URL:.
37. European Committee for Medicinal Products For Human Use. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application. London: European Medicines Agency, 2004. Publication No. EMEA/CPMP/VEG/ 4717/2003-Rev.1. URL:.
38. Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361: 2414-23.
39. MacKenzie JS,. Influenza subunit vaccine: antibody responses to one and two doses of vaccine and length of response, with particular reference to the elderly. Br Med J 1977; 1: 200-2. (Pubitemid 8018413)
40. Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ, Beyer WE, Tilanus HW, Kemmeren MH, et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol 2000; 61: 85-93. (Pubitemid 30191231)
41. Versluis DJ, Beyer WE, Masurel N, Weimar W, Kramer P, Diderich PP,. Value of booster immunisation with influenza vaccine in patients undergoing haemodialysis. Br Med J (Clin Res Ed) 1987; 294: 348. (Pubitemid 17007403)
42. Rautenberg P, Proppe D, Schutte A, Ullmann U,. Influenza subtype-specific immunoglobulin A and G responses after booster versus one double-dose vaccination in hemodialysis patients. Eur J Clin Microbiol Infect Dis 1989; 8: 897-900. (Pubitemid 19265878)
43. Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciu H, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993; 11: 1-5. (Pubitemid 23086839)
44. Song JY, Cheong HJ, Ha SH, Kee SY, Jeong HW, Kim WJ,. Active influenza immunization in hemodialysis patients: comparison between single-dose and booster vaccination. Am J Nephrol 2006; 26: 206-11.
45. Tanzi E, Amendola A, Pariani E, Zappa A, Colzani D, Logias F, et al. Lack of effect of a booster dose of influenza vaccine in hemodialysis patients. J Med Virol 2007; 79: 1176-9. (Pubitemid 47015418)
46. Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R,. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 2007; 25: 3955-61. (Pubitemid 46616991)
47. Cools HJ, Gussekloo J, Remmerswaal JE, Remarque EJ, Kroes AC,. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial. J Med Virol 2009; 81: 908-14.
48. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198: 650-8.
49. Sullivan SP, Koutsonanos DG, del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010; 16: 915-20.